Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
Band of Parents
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01419834
First received: August 17, 2011
Last updated: May 27, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2016
  Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)